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Pneumocystis and Severe Acute 
Respiratory Syndrome Coronavirus 2 
Coinfection: A Case Report and Review 
of an Emerging Diagnostic Dilemma
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We present a case of a critically ill patient with coronavirus dis-
ease 2019 (COVID-19) found to have acquired immune defi-
ciency syndrome and Pneumocystis jirovecii pneumonia (PCP). 
Coronavirus disease 2019 and PCP co-occurrence is increasingly 
reported and may complicate diagnostic and therapeutic strategies. 
Patients with severe COVID-19 should be screened for underlying 
immunocompromise and coinfections should be considered.
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With mounting global cases of coronavirus disease 2019 
(COVID-19), there has been increasing recognition of fungal 
coinfection complicating COVID-19 care. Although Aspergillus 
spp appears to be the predominant fungal pathogen in persons 
with COVID-19 pneumonia [1], there are emerging reports of 
Pneumocysits jirovecii pneumonia (PCP) co-occurring with or 
after COVID-19.
In this study, we present a case of a patient hospitalized with 
hypoxemic respiratory failure attributed to COVID-19 and was 
found to have a new diagnosis of acquired immune deficiency 
syndrome (AIDS) and PCP. We review all published literature 
to date of co-occurring COVID-19 and PCP.
CASE REPORT
A 36-year-old man with no known past medical history pre-
sented to an emergency room complaining of shortness of 
breath, fever, nausea, and diarrhea for 3 weeks. Additional 
review of systems was positive for chills, sinus congestion, sore 
throat, and cough. He denied anosmia and chest pain. He was 
Hispanic and lived with 2 relatives who were asymptomatic. 
He worked in construction and reported close contacts with 
coworkers with similar symptoms.
On admission, his temperature was 38.7°C, heart rate 121 
beats per minute, blood pressure 94/59 mmHg, respiratory rate 
40 breaths per minute, and oxygen saturation 89% on 15L high 
flow nasal cannula, improved in prone positioning. He was ill-
appearing, in respiratory distress, and without abnormal lung 
sounds. The white blood cell count was 8600/μL (reference 
range, 4800 to 10  800); absolute lymphocyte count was 400/
μL (reference range, 1200 to 3400); absolute neutrophil count 
was 7800/μL (reference, 1400 to 6500); C-reactive protein was 
197.72 mg/L (reference, <10); ferritin was 1276.1 ng/mL (ref-
erence range, 10–300); lactate dehydrogenase was 789 IU/L 
(reference range, 100–220); and procalcitonin was 1.87 ng/mL 
(reference,  <0.50). A  swab for influenza A  and B viruses was 
negative. An oropharyngeal swab for severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) polymerase chain re-
action (PCR) was positive. Chest radiograph showed diffuse 
hazy pulmonary opacifications. A contrasted computed tomog-
raphy angiography of the chest showed diffuse upper and lower 
lobe ground-glass alveolar airspace disease without pulmonary 
embolism.
The patient was admitted to intensive care and started on 
remdesivir, as well as cefepime and vancomycin for possible 
bacterial pneumonia. Over the next 48 hours he experienced 
persistent hypoxemia requiring intubation and transfer to our 
facility. As part of our institutional protocols for patients ad-
mitted with COVID-19 at the time of this encounter, routine 
screening with a fourth-generation human immunodeficiency 
virus (HIV)-1/2 antigen/antibody test was performed and reac-
tive. Reflex HIV ribonucleic acid testing revealed a viral load of 
578 876 copies/mL. His absolute CD4 cell count was <10 cells/
μL and 2% of lymphocytes. Due to the patient’s critical illness 
and clinical condition, additional social and medical history was 
unobtainable, but medical record review did not report a history 
of HIV and noted no outpatient medications. A new chest radio-
graph was reported as heterogeneous bilateral lung opacities with 
scattered air bronchograms (Figure 1), but treating providers felt 
the opacities were less dense than expected for COVID-19 and 
for his level of hypoxemia. He continued remdesivir via emer-
gency use authorization, received a transfusion of COVID-19 
convalescent plasma, and antibacterial medications were nar-
rowed to ceftriaxone and azithromycin.
Given the patient’s prolonged, subacute symptoms and 
x-ray findings, an evaluation for PCP was undertaken and
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he was started on empiric trimethoprim-sulfamethoxazole 
and prednisone. A  tracheal aspirate acid-fast stain, bacte-
rial culture, and P jirovecii direct fluorescent antibody stain 
(DFA) were all negative. Positive serological studies included 
(1→3)-β-d-glucan >500 pg/mL as well as a weakly positive 
serum histoplasma antigen that was below the level of quan-
tification. A QuantiFERON-TB Gold test was indeterminate. 
Urine histoplasma antigen and blood cultures for bacteria 
and molds were negative. On hospital day 7, he underwent 
bronchoscopy with bronchial alveolar lavage that yielded 
positive Pneumocystis DFA and PCR tests, positive SARS-
CoV-2 PCR, and bacterial, fungal, and mycobacterial cul-
tures that remain negative to date.
The patient completed a course of remdesivir. He received 
a 21-day course of trimethoprim-sulfamethoxazole and pred-
nisone for PCP, and he started dolutegravir with combina-
tion tenofovir alafenamide/emtricitabine for HIV. His course 
was complicated by ventilator-associated pneumonia due to 
Pseudomonas aeruginosa, labial ulcer due to herpes simplex 
virus type 1, persistent hypoxemia, and ongoing fevers. He 
was evaluated for extracorporeal membrane oxygenation but 
deemed not to be a candidate due to his prolonged ventilation 
and his immunocompromised state. He continued to experi-
ence refractory hypoxemia despite maximal ventilator settings, 
paralytic agents, and prone positioning. On hospital day 26, he 
developed asystolic cardiac arrest and died. No autopsy was 
performed.
Patient Consent Statement
Consent was unable to be obtained from the patient due to pa-
tient being intubated and altered throughout his hospitalization. 
No family or next of kin was available, and, if they had been, 
obtaining consent would have risked potentially unwanted 
disclosure of the patient’s HIV status. All identifying details of 
the patient have been removed in accordance with our insti-
tutional policy and Oxford University Press publishing policy. 
Ethical board approval was not believed to be indicated because 
this did not involve human subjects research.
Literature Review
A literature search of Medline with the string “[COVID-19 
and pneumocystis] or [SARS-COV-2 and pneumocystis] or 
[COVID-19 and PJP] or [SARS-COV-2 and PJP] or [COVID-
19 and PCP] or [SARS-COV-2 and PCP]” was conducted in 
September 2020. This search yielded 28 results (Supplementary 
Figure 1). Thirteen articles were case reports, 5 of which 
were case reports of patients with both COVID-19 and PCP 
(Table 1). Of these, 3 were also HIV positive. Two cases were 
in people newly diagnosed with HIV, underscoring the need 
for HIV testing in individuals hospitalized for COVID-19 who 
would not be expected to have a severe course of illness. In one 
case, the patient was diagnosed with COVID-19, treated with 
tocilizumab and glucocorticoids, and later diagnosed with PCP, 
raising the possibility that immunomodulatory treatment for 
COVID-19 contributed to the development of PCP [2]. The 
other 8 case reports described cases of either PCP or COVID-
19 and the challenge in distinguishing between them.
DISCUSSION
This case emphasizes that PCP and COVID-19 can present as 
co-occurring disease processes and a broad differential should 
be maintained, especially in immunocompromised patients. 
Pneumocystis jirovecii is an opportunistic fungal pathogen that 
primarily causes disease in immunocompromised individuals. 
Although historically associated with advanced HIV, PCP now 
often impacts persons who are immunosuppressed for other 
reasons as well, including malignancy [3], organ transplant 
[4], and those requiring other immunosuppressive drugs, par-
ticularly corticosteroids [5]. All 5 previously reported cases of 
COVID-19 and PCP coinfection identified during our litera-
ture review had a documented immunocompromising condi-
tion. It is notable that none of the other cases of COVID-19 and 
PCP died. This may be attributable to extent of immunosup-
pression in our patient as well as his late presentation to care.
Pneumocystis jirovecii pneumonia and moderate-to-severe 
COVID-19 share many clinical characteristics, making them 
difficult to distinguish. Both often present with fever, cough, 
and hypoxia [6] and can have a wide range of radiographic 
findings including diffuse ground-glass opacities [7]. The simi-
larities in presentation may be due to similar underlying mech-
anisms of pathogenicity between the 2 infections and their 
interaction with pulmonary surfactant [8]. Given these similar 
findings, there is a growing recognition of PCP as a COVID-19 
mimicker in severely ill patients [9].
Figure 1. Chest X-ray on transfer to our facility, showing diffuse hazy opacities.
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In the case of our patient, the 3-week symptom duration be-
fore presentation was atypically long for COVID-19. For com-
parison, a large series of patients with COVID-19 alone reported 
a median 7  days of symptoms preceding hospitalization [10]. 
Coinfection with both SARS-CoV-2 and P jirovecii can lead to 
diagnostic dilemmas. Although COVID-19 testing is now readily 
available via nasopharyngeal swabs with fast turnaround time by 
most hospital laboratories [11, 12], PCP is less easy to diagnose. 
Bronchial alveolar lavage fluid remains the gold standard for PCP 
diagnosis due higher sensitivity [13], but performing a bronchos-
copy to obtain a bronchial alveolar lavage specimen is an invasive 
procedure that cannot always be readily performed in severely 
hypoxic patients, and it requires additional procedural caution 
due to the risk of aerosolization of SARS-CoV-2. Although the 
serum fungal marker 1,3-β-d-glucan can be used to aid in the di-
agnosis of PCP [14], additional testing and a compatible clinical 
presentation are required to confirm the diagnosis. Colonization 
with P jirovecii is common in patients with COVID-19, a finding 
that may further impact challenging diagnostic scenarios. A re-
cent study of 108 critically ill patients with COVID-19 found that 
9% had a positive PCR test for P jirovecii on bronchial alveolar 
lavage [15]. The use of corticosteroids for severe COVID-19 may 
further delay diagnosis of co-occurring PCP, because such pa-
tients may theoretically experience transient improvement, given 
the known beneficial effect of steroids in severe PCP. As targeted 
immunomodulators are studied in COVID-19, physicians should 
be mindful of the risk they may pose for PCP. For example, the 
anti-interleukin-6 monoclonal antibody tocilizumab, which was 
pursued as a potentially promising therapy for COVID-19, has 
been associated with PCP in the treatment of rheumatoid ar-
thritis (0.28 events per 100 patient-years) [16].
Finally, this case of COVID-19 and AIDS in a Latinx male high-
lights the disparities intertwined with both COVID-19 and HIV 
in the United States. Coronavirus disease 2019 has disproportion-
ately affected the Latinx and black communities in the United 
States [17]— populations that experience a greater incidence and 
prevalence of HIV, have a high rate of progression to AIDS, and 
encounter barriers to HIV testing and care [18–21]. The HIV 
testing efforts and the continuity of care among these vulnerable 
populations may be disrupted as healthcare resources are shifted 
toward the pandemic and traditional models of healthcare de-
livery are redesigned [22, 23]. However, the pandemic also pre-
sents new opportunities to engage patients in HIV screening and 
other preventive care as they seek COVID-19 testing or treatment. 
Incorporating HIV screening of all patients admitted for COVID-
19 into institutional protocols is a sensible approach that would 
benefit individual patients and impact public health disparities.
CONCLUSIONS
In summary, there is increasing recognition of PCP 
co-occurring with or succeeding severe COVID-19, primarily 
in immunocompromised individuals. Diagnostic uncertainty 
and anchoring biases can potentially delay diagnosis due to sub-
stantial overlap in the clinical presentation. Providers caring for 
patients with severe COVID-19 should retain a broad differen-
tial diagnosis if the clinical syndrome is atypical for COVID-
19 or in patients with immunocompromising conditions. It is 
sensible to consider routine testing of HIV in all patients ad-
mitted with COVID-19 as a means of mitigating this diagnostic 
dilemma and benefitting our public health efforts.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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